secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001171843-24-000967
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit
--------------------------------------------------------------------------------

- ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).
- 2024 guidance: ORLADEYO revenue $380-$400M; expects operating profit in 2024, positive EPS and cash flow in 2H 2025.
- GAAP net loss Q4 $61.7M ($0.31), FY2023 $226.5M ($1.18); non-GAAP net loss Q4 $56.4M ($0.28).
- R&D expenses fell to $70.1M Q4 (-4% yoy); SG&A rose to $64.4M Q4 (+28% yoy) on commercial expansion.
- Cash $390.8M at Dec 31, 2023; net cash use $8.6M in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/0001171843-24-000967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/f8k_022624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer